ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
66.894,57
-0,07%
Brent Oil
83,76
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vistagen Therapeutics Inc (VTGN)

  7. Vistagen Therapeutics Inc (VTGN) Notícias

VTGN

Vistagen Therapeutics (VTGN)

Vistagen Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VTGN
DataHoraFonteTítuloCódigoCompanhia
07/05/202409:30Business WireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
25/04/202409:30Business WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueNASDAQ:VTGNVistagen Therapeutics Inc
09/04/202409:30Business WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
01/04/202409:30Business WireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2NASDAQ:VTGNVistagen Therapeutics Inc
11/03/202409:30Business WireVistagen to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VTGNVistagen Therapeutics Inc
06/03/202420:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
01/03/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VTGNVistagen Therapeutics Inc
28/02/202410:30Business WireVistagen to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
14/02/202420:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
14/02/202418:51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistagen Therapeutics Inc
13/02/202418:52Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VTGNVistagen Therapeutics Inc
13/02/202418:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
13/02/202418:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
13/02/202418:20Business WireVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
12/02/202420:27Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistagen Therapeutics Inc
06/02/202410:30Business WireVistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024NASDAQ:VTGNVistagen Therapeutics Inc
27/12/202310:30Business WireVistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic PainNASDAQ:VTGNVistagen Therapeutics Inc
09/11/202318:30Business WireVistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial ResultsNASDAQ:VTGNVistagen Therapeutics Inc
08/11/202310:30Business WireVistagen to Present at Stifel 2023 Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
07/11/202310:30Business WireVistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific ConferencesNASDAQ:VTGNVistagen Therapeutics Inc
06/11/202323:46Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
06/11/202310:00Business WireVistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023NASDAQ:VTGNVistagen Therapeutics Inc
03/11/202321:14Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
05/10/202309:30Business WireVistagen to Present at Jefferies Inaugural Biotech CNS/Neuro SummitNASDAQ:VTGNVistagen Therapeutics Inc
03/10/202317:40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VTGNVistagen Therapeutics Inc
02/10/202308:30Business WireVistagen Announces Pricing of $100 Million Underwritten OfferingNASDAQ:VTGNVistagen Therapeutics Inc
12/09/202309:30Business WireVistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric DisorderNASDAQ:VTGNVistagen Therapeutics Inc
05/09/202310:00Business WireVistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in JapanNASDAQ:VTGNVistagen Therapeutics Inc
22/08/202309:30Business WireVistagen Appoints Cindy Anderson as Chief Financial OfficerNASDAQ:VTGNVistagen Therapeutics Inc
10/08/202317:21Business WireSubsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial ResultsNASDAQ:VTGNVistagen Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VTGN

Seu Histórico Recente

COIN
PETEUR
Pet Token
NASDAQ
FIZECX
Senior Loan Select Close...
BIT
F29122
Vontobel Financial Produ...
BIT
GS0173
Goldman Sachs
USOTC
ARAAF
Aclara Resources (PK)
USOTC
CERAF
Ceres Acquisition (QX)
COIN
GPXXUST
Grandprixworld token
BIT
F18010
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados